Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TNK2 | Q07912 | 4/20 | 0.40 |
| ▸ | PKN1 | Q16512 | 3/20 | 0.37 |
| ▸ | PAK4 | O96013 | 2/20 | 0.37 |
| ▸ | RIPK2 | O43353 | 5/20 | 0.37 |
| ▸ | NOD2 | Q9HC29 | 5/20 | 0.37 |
| ▸ | ACVR1 | Q04771 | 3/20 | 0.37 |
| ▸ | SRC | P12931 | 1/20 | 0.36 |
| ▸ | PAK1 | Q13153 | 3/20 | 0.36 |
| ▸ | PAK3 | O75914 | 2/20 | 0.36 |
| ▸ | PAK2 | Q13177 | 2/20 | 0.36 |
| ▸ | CDK2 | P24941 | 1/20 | 0.36 |
| ▸ | KDR | P35968 | 1/20 | 0.36 |
| ▸ | CAMK2D | Q13557 | 1/20 | 0.35 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.35 |
| ▸ | WEE1 | P30291 | 1/20 | 0.35 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14682102 | 0.94 | TNK2 (0.40) | TNK2PKN1PAK4RIPK2NOD2 | |
| SCHEMBL15785355 | 0.86 | TNK2 (0.41) | TNK2PKN1PAK4RIPK2NOD2 | |
| SCHEMBL15036122 | 0.79 | RIPK2 (0.47) | TNK2RIPK2NOD2ACVR1SRC | |
| SCHEMBL15041707 | 0.79 | RIPK2 (0.43) | TNK2RIPK2NOD2ACVR1PTK2 | |
| SCHEMBL15787914 | 0.75 | RIPK2 (0.43) | TNK2PKN1PAK4RIPK2NOD2 | |
| SCHEMBL14682001 | 0.75 | RIPK2 (0.47) | TNK2PKN1PAK4RIPK2NOD2 | |
| SCHEMBL14682109 | 0.72 | CDK2 (0.43) | TNK2PKN1PAK4PAK1CDK2 | |
| SCHEMBL15281053 | 0.72 | RIPK2 (0.46) | TNK2RIPK2NOD2ACVR1SRC | |
| SCHEMBL15041506 | 0.71 | RIPK2 (0.42) | TNK2PKN1PAK4RIPK2NOD2 | |
| SCHEMBL14682018 | 0.70 | PAK3 (0.43) | TNK2PKN1PAK4PAK1PAK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130158043-A1 | PAK INHIBITORS FOR THE TREATMENT OF CANCER | AFRAXIS, INC. (US) | 2013-06-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130158043-A1 | PAK INHIBITORS FOR THE TREATMENT OF CANCER | PAK5, PAK2, PAK6 | TNK2 7/4885PKN1 326/4885PAK4 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.